Press releases
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.31 |
---|---|
High | 0.31 |
Low | 0.31 |
Bid | 0.308 |
Offer | 0.388 |
Previous close | 0.31 |
Average volume | 500.00 |
---|---|
Shares outstanding | 13.90m |
Free float | 13.74m |
P/E (TTM) | -- |
Market cap | 5.11m USD |
EPS (TTM) | -4.87 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 07:02 BST.
More ▼